NX-13 500mg IR ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
97潰瘍性大腸炎1

97. 潰瘍性大腸炎


臨床試験数 : 2,630 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04862741
(ClinicalTrials.gov)
May 5, 202110/3/2021Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative ColitisA Randomized, Double-blind Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative ColitisUlcerative ColitisDrug: NX-13 250mg IR;Drug: NX-13 500mg IR;Drug: NX-13 500mg MR;Drug: PlaceboLandos Biopharma Inc.NULLCompleted18 Years65 YearsAll39Phase 1United States;Ukraine